Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "End-stage renal failure" wg kryterium: Temat


Wyświetlanie 1-2 z 2
Tytuł:
Effect of a bicarbonate-buffered peritoneal dialysis solution on clinical and laboratory indices of dialysis adequacy
Autorzy:
Chmielewski, Michał
Bielińska-Ogrodnik, Dorota
Jagodziński, Piotr
Lichodziejewska-Niemierko, Monika
Powiązania:
https://bibliotekanauki.pl/articles/895747.pdf
Data publikacji:
2020-05-29
Wydawca:
Gdański Uniwersytet Medyczny
Tematy:
peritoneal dialysis
acid-base balance
end-stage renal failure
bicarbonate-based solutions
Opis:
Background: Biocompatible fluids were introduced to improve dialysis and patient outcome in end-stage renal disease. However, being buffered with lactate, they may insufficiently correct metabolic acidosis, and lead to changes in peritoneum structure. Bicarbonate buffered fluids might mitigate these complications. The aim of the study was to evaluate the influence of a bicarbonate dialysis fluid on clinical and laboratory indices of dialysis adequacy. Material and methods: 20 prevalent peritoneal dialysis (PD) patients created two groups. One group continued on lactate fluid, the other changed to bicarbonate solution. Clinical and laboratory indices of dialysis adequacy were evaluated at baseline, and at six weeks intervals for 24 weeks. Results: In bicarbonate group, pH was 7.36±0.03, HCO3 22.1±1.8 mmol/l at baseline and 7.36±0.04 and 21.2± 2.3 mmol/l at 24 weeks, while in controls pH equaled 7.35±0.12, HCO3 22.2±1.4 mmol/l, at baseline, and 7.40±0.03, and 22.3±1.8 mmol/l, at 24 weeks, with no significant differences. Dialysis adequacy (urea Kt/V), urine output and dialysis ultrafiltration did not differ between the groups, either at baseline or at study termination. Conclusions: Bicarbonate PD solution appears to be similar to standard fluid in the impact on hydration status and on acid/base balance. Longitudinal studies are needed to assess long-term advantages of these biocompatible solutions.
Źródło:
European Journal of Translational and Clinical Medicine; 2020, 3, 1; 11-15
2657-3148
2657-3156
Pojawia się w:
European Journal of Translational and Clinical Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Long-time survival of a female with primary amyloidosis treated by peritoneal dialysis
Autorzy:
Grzebalska, Agnieszka M.
Sak, Jarosław
Prystupa, Andrzej
Książek, Andrzej
Powiązania:
https://bibliotekanauki.pl/articles/972730.pdf
Data publikacji:
2017
Wydawca:
Instytut Medycyny Wsi
Tematy:
kidney failure
peritoneal dialysis
end-stage renal disease
Amyloidosis
Opis:
Introduction. Amyloidosis, both primary and secondary, is a systemic disease characterized by extracellular deposition of fibrillar protein in vital organs, leading to their injury and even insufficiency. It results in a poor diagnosis, especially for patients with primary amyloidosis. Kidney involvement is typical and usually manifests by proteinuria, mainly nephrotic range, leading to end-stage renal disease (ESRD). Patients with ESRD need renal replacement therapy (RRT). Some data claim that better results and longer patient, survival are observed in peritoneal dialysed rather than in haemodialysed patients. Case report. The case is described of 19-year-old Caucasian woman with primary amyloidosis. Inherited primary amyloidosis with abnormal apolipoprotein A-I was established. The patient was successfully treated with peritoneal dialysis for 87 months. After this period, she was transferred for haemodialysis. Such a long survival time on peritoneal dialysis (PD) in a patient with primary amyloidosis has not been found. It is believed that the lowering of immunoglobulin levels in blood and normalization of total protein in serum effectively removed, through dialysate, the pathological polyclonal proteins. This effect probably also sustained cardio-circulatory sufficiency of the patient and significantly prolonged her survival. Conclusion. Peritoneal dialysis is an effective and recommended method of treatment in patients suffering from primary amyloidosis. Peritoneal dialysis should be the first choice therapy in ESRD patient; contrary to haemodialysis, peritoneal dialysis removes pathological proteins and allows the avoidance of intra-dialytic hypotension.
Źródło:
Journal of Pre-Clinical and Clinical Research; 2017, 11, 1; 22-24
1898-2395
Pojawia się w:
Journal of Pre-Clinical and Clinical Research
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-2 z 2

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies